Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine, Inc. develops genetic medicines using its proprietary Prime Editing platform, which is designed to make targeted edits within genes. News about PRME centers on its pipeline for genetically defined diseases, including PM577 for Wilson Disease, PM647 for Alpha-1 Antitrypsin Deficiency and PM359, an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease.
Company updates also cover financial results, regulatory interactions, clinical-data publications, investor conference participation and finance leadership changes. Additional recurring themes include an in vivo cystic fibrosis program supported by the Cystic Fibrosis Foundation and Prime Edited CAR-T product development with Bristol Myers Squibb for hematology, immunology and oncology.
Prime Medicine, a leading biotechnology company listed on Nasdaq under the symbol PRME, announced that Dr. Keith Gottesdiener, President and CEO, will present a corporate overview at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 9:50 a.m. ET in Boston, MA. This presentation will highlight the company's innovative approach to one-time curative genetic therapies utilizing Prime Editing technology, which can potentially address around 90 percent of disease-causing genetic mutations. A live audio webcast will be available on their website, with a replay accessible for 30 days following the event.
Prime Medicine, Inc. (Nasdaq: PRME) announced significant advancements in its Prime Editing technology, focusing on preclinical proof-of-concept for treating diseases like Friedrich’s ataxia and cystic fibrosis. Preliminary safety analyses show no off-target activity in Wilson’s disease cells, reinforcing the platform's specificity. The company also reported progress in integrating kilobase-sized DNA into human T cells and efficient delivery methods for various tissues in rodents. With a strong cash position expected to fund operations into 2025, multiple catalysts are anticipated throughout 2023.
Prime Medicine, Inc. (Nasdaq: PRME) announced that CEO Keith Gottesdiener will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 a.m. PT in San Francisco, CA. The event will be available via live audio webcast on the company's website, with a replay accessible for 30 days post-presentation. Prime Medicine focuses on innovative genetic therapies using Prime Editing technology, which aims to address a wide range of diseases by potentially repairing 90% of known genetic mutations.
Prime Medicine, Inc. (Nasdaq: PRME) has successfully completed its upsized initial public offering, issuing 10,294,118 shares at $17.00 each, raising approximately $175 million before expenses. The underwriters also hold a 30-day option to purchase an additional 1,544,117 shares. Shares started trading on Nasdaq on October 20, 2022. This offering aims to fund the development of Prime Editing technology, which has the potential to address a wide range of genetic diseases by correcting mutations.
Prime Medicine, Inc. (Nasdaq: PRME) has priced its upsized initial public offering of 10,294,118 shares at $17.00 each, aiming to raise approximately $175 million before expenses. The offering, managed by J.P. Morgan, Goldman Sachs, Morgan Stanley, and Jefferies, will commence trading on the Nasdaq Global Market on October 20, 2022, and is set to close on October 24, 2022. The company focuses on innovative genetic therapies using Prime Editing technology, which targets a wide range of genetic diseases.